A novel non-azole topical treatment reduces Malassezia numbers and associated dermatitis: a short term prospective, randomized, blinded and placebo-controlled trial in naturally infected dogs

BackgroundMalassezia yeast overgrowth on the skin is a common and often recurrent cause of dermatitis in dogs; it can be an exacerbating factor of atopic dermatitis. Anti-fungal drugs have been a standard treatment, but there is some concern that resistance may be evolving in a spectrum of Malassezia species. Safe, efficient and easy-to-use alternatives are needed.ObjectivesTo assess if a commercially available topical non-azole solution applied to paws affected by Malassezia-associated dermatitis (MAD), could ameliorate Malassezia numbers and associated signs over a short term (14day) trial.AnimalsEighteen dogs with MAD affecting at least two paws.MethodsThe study design was prospective, randomized, blinded and placebo-controlled, using a split-body protocol. Dogs were treated once daily with the test solution on one paw and placebo on the other. Dogs were examined at days 0 and 143. The primary end-point was Malassezia numbers assessed cytologically. Secondary end-points were clinical scores for lesion severity and pruritus as assessed by a pruritus Visual Analog Scale (PVAS). Owner compliance and adverse effects were assessed.ResultsThere was a statistically significant reduction in Malassezia numbers and clinical scores for paws treated with the test solution versus placebo. No statistical difference in PVAS was found.ConclusionDaily topical application of the test solution was effective in reducing the Malassezia burden, as well as improving clinical scores in dogs with MAD of the paws. No adverse effects were reported and owners described the product as either easy or very easy to use.